EFFICACY OF ANTI-DIABETIC DRUGS ON PREVENTION OF MYOCARDIAL INFARCTION IN DIABETIC SUBJECTS

Abstract

Background: Compared to subjects without diabetes mellitus, those with the disease are more likely to need repeated PCI (percutaneous coronary intervention).
Aim: The purpose of this study was to evaluate and compare the effectiveness of glucose-lowering medications on the secondary prevention of myocardial infarction in individuals with type 2 diabetes.
Methods: During the specified study period, 200 subjects who were over or equal to 30 years old and had percutaneous coronary intervention at the Institute were evaluated. Based on their anti-diabetic medication prescription records, the 200 participants were split up. The rate of coronary revascularization was the primary outcome evaluated in the research participants.
Results: Among the 200 participants in the study, those taking metformin had a significantly lower risk of needing percutaneous coronary intervention. Thiazolidinedione (TZD)-treated obese individuals with a BMI of ≥25 kg/m2 had a lower risk of repeated revascularization than non-TZD-treated individuals (p<0.05). Regardless of their BMI, subjects taking metformin had a lower risk of requiring revascularization. Meglitinide, insulin, and alpha-glucosidase inhibitors were associated with the need for repeated percutaneous coronary interventions.
Conclusion: Individuals with diabetes treated with metformin and obese individuals treated with thiazolidinedione had a significantly lower risk of requiring revascularization. According to these results, doctors should choose the right anti-diabetic medications for secondary prevention of coronary artery disease.